Rollover Protocol for Prior SU011248 Protocols

NCT00798889 | Completed Results

• 1 other identifier: A6181030
• Study Type: interventional
• Target: 314
• Locations: 11 countries
• Sites: 59

Brief Summary

The objective of this protocol is to provide SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol

Conditions

Solid Tumors

Keywords

Solid tumors

Outcome Measures

Primary Outcomes (1)

• Duration of Treatment

  Baseline up to Day 28 after last dose of study treatment

Study Arms (1)

Sunitinib

EXPERIMENTAL

Drug: Sunitinib

Interventions

Sunitinib DRUG

Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol

Sunitinib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Prior SU011248 Protocol.
• Eligible to continue SU011248 treatment.

You may not qualify if:

• Uncontrolled CNS metastasis.
• Unfit to receive SU011248.

Sponsors & Collaborators

• Pfizer: lead

Study Sites (59)

Pfizer Investigational Site

Birmingham, Alabama, 35233-2115, United States

Location

Pfizer Investigational Site

Birmingham, Alabama, 35233, United States

Location

Pfizer Investigational Site

Birmingham, Alabama, 35294, United States

Location

Pfizer Investigational Site

Los Angeles, California, 90033, United States

Location

Pfizer Investigational Site

Los Angeles, California, 90095, United States

Location

Pfizer Investigational Site

San Francisco, California, 94115-1705, United States

Location

Pfizer Investigational Site

San Francisco, California, 94115, United States

Location

Pfizer Investigational Site

Santa Monica, California, 90404, United States

Location

Pfizer Investigational Site

Aurora, Colorado, 80045, United States

Location

Pfizer Investigational Site

Indianapolis, Indiana, 46202, United States

Location

Pfizer Investigational Site

Boston, Massachusetts, 02114, United States

Location

Pfizer Investigational Site

Boston, Massachusetts, 02115, United States

Location

Pfizer Investigational Site

Boston, Massachusetts, 02215, United States

Location

Pfizer Investigational Site

Ann Arbor, Michigan, 48109-0843, United States

Location

Pfizer Investigational Site

Detroit, Michigan, 48201, United States

Location

Pfizer Investigational Site

Farmington Hills, Michigan, 48334, United States

Location

Pfizer Investigational Site

Minneapolis, Minnesota, 55455-0392, United States

Location

Pfizer Investigational Site

St Louis, Missouri, 63110, United States

Location

Pfizer Investigational Site

Albuquerque, New Mexico, 87131-0001, United States

Location

Pfizer Investigational Site

Albuqurque, New Mexico, 87106, United States

Location

Pfizer Investigational Site

New York, New York, 10021, United States

Location

Pfizer Investigational Site

New York, New York, 10022, United States

Location

Pfizer Investigational Site

New York, New York, 10032, United States

Location

Pfizer Investigational Site

Durham, North Carolina, 27710, United States

Location

Pfizer Investigational Site

Cleveland, Ohio, 44195, United States

Location

Pfizer Investigational Site

Philadelphia, Pennsylvania, 19111, United States

Location

Pfizer Investigational Site

Myrtle Beach, South Carolina, 29572, United States

Location

Pfizer Investigational Site

Franklin, Tennessee, 37067, United States

Location

Pfizer Investigational Site

Gallatin, Tennessee, 37066, United States

Location

Pfizer Investigational Site

Hermitage, Tennessee, 37076, United States

Location

Pfizer Investigational Site

Lebanon, Tennessee, 37087, United States

Location

Pfizer Investigational Site

Murfreesboro, Tennessee, 37130, United States

Location

Pfizer Investigational Site

Nashville, Tennessee, 37203, United States

Location

Pfizer Investigational Site

Nashville, Tennessee, 37205, United States

Location

Pfizer Investigational Site

Nashville, Tennessee, 37207, United States

Location

Pfizer Investigational Site

Nashville, Tennessee, 37211, United States

Location

Pfizer Investigational Site

Nashville, Tennessee, 37212, United States

Location

Pfizer Investigational Site

Nashville, Tennessee, 37232, United States

Location

Pfizer Investigational Site

Smyrna, Tennessee, 37167, United States

Location

Pfizer Investigational Site

Dallas, Texas, 75246, United States

Location

Pfizer Investigational Site

Houston, Texas, 77030-4009, United States

Location

Pfizer Investigational Site

Madison, Wisconsin, 53792, United States

Location

Pfizer Investigational Site

Randwick, New South Wales, 2031, Australia

Location

Pfizer Investigational Site

East Melbourne, Victoria, 3002, Australia

Location

Pfizer Investigational Site

Heidelberg, Victoria, 3084, Australia

Location

Pfizer Investigational Site

Montreal, Quebec, H2L 4M1, Canada

Location

Pfizer Investigational Site

Villejuif, 94805, France

Location

Pfizer Investigational Site

Thessaloniki, 564 03, Greece

Location

Pfizer Investigational Site

Milan, 20133, Italy

Location

Pfizer Investigational Site

Milan, 20141, Italy

Location

Pfizer Investigational Site

Nijmegen, Gelderland, 6525 GA, Netherlands

Location

Pfizer Investigational Site

Singapore, Singapore, 308433, Singapore

Location

Pfizer Investigational Site

Lund, Sweden

Location

Pfizer Investigational Site

Stockholm, Sweden

Location

Pfizer Investigational Site

Sankt Gallen, CH-9007, Switzerland

Location

Pfizer Investigational Site

Leeds, LS9 7TF, United Kingdom

Location

Pfizer Investigational Site

London, NW1 2PG, United Kingdom

Location

Pfizer Investigational Site

London, SW3 6JJ, United Kingdom

Location

Pfizer Investigational Site

Newcastle upon Tyne, NE4 6BE, United Kingdom

Location

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Interventions

Sunitinib

Intervention Hierarchy (Ancestors)

Pyrroles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Results Point of Contact

• Title: Pfizer ClinicalTrials.gov Call Center
• Organization: Pfizer, Inc.

ClinicalTrials.gov_Inquiries@pfizer.com

1-800-718-1021

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 25, 2008
• First Posted: November 26, 2008
• Study Start: March 1, 2004
• Primary Completion: December 1, 2011
• Study Completion: December 1, 2011
• Last Updated: January 21, 2013
• Results First Posted: January 21, 2013

Record last verified: 2012-12

Locations

FR (1); IT (2); NL (1); SG (1); GR (1); SE (2); GB (4); US (42); CA (1); AU (3); CH (1)